ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the second quarter ended June 30, 2016 and provided a corporate update.
“During the second quarter, we continued to sharpen our focus on clinical progress and simplifying our corporate structure,” said Adi Mohanty, Co-Chief Executive Officer. “Our key therapeutic programs, Renevia® in medical aesthetics and OpRegen® in dry AMD, continue to advance in the clinic, and we expect additional meaningful milestones from these programs in the second half of 2016.
“During the second quarter, we continued to sharpen our focus on clinical progress and simplifying our corporate structure,” said Adi Mohanty, Co-Chief Executive Officer. “Our key therapeutic programs, Renevia® in medical aesthetics and OpRegen® in dry AMD, continue to advance in the clinic, and we expect additional meaningful milestones from these programs in the second half of 2016.
